Foghorn Therapeutics Inc

FHTXNASDAQ · Pharmaceutical Preparations

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

58.7M

on 2026-06-30, from 42.6M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

Newest

$300.0M

S-3 of 2025-01-24. 1 prospectus supplement filed under it since. S-3 ↗

$100.0M

TD Cowen, agreement of 2025-03-20. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

The 10-Q filed 2026-08-06 is not read yet.

Cash

3.2 quarters

$68.1M on 2026-06-30 ÷ $21.1M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
Date	What	Shares	Price	Gross	Filing
2026-01-09	Private placement incl. 5.42M pre-funded	10,842,500	not read	$50.0M	8-K ↗
2026-01-09	Public offering incl. 5.42M pre-funded, with warrants at $13.42	7,451,564	$6.71	$50.0M	424B5 ↗